HOME > TOP STORIES

TOP STORIES

REGULATORY R&D Tax Credit Revamp (1): New Scheme for Open Innovation Research Significant in 3 Ways

January 20, 2015
REGULATORY PMDA Head Expresses Full Support for AMED

January 19, 2015
ORGANIZATION JPMA Notifies of Unfavorable Expressions for Disease Awareness Ads

January 16, 2015
ORGANIZATION Pharma Leader Nakayama Hails Tax Plan, Says His New Year Remarks Misleading

January 15, 2015
INTERVIEW EFPIA Japan Chairman Says Drug Costs Won’t Explode

January 14, 2015
ORGANIZATION Wholesalers Must Revamp Biz Model to Cope with Change in Sales Mix: JPWA Chief

January 14, 2015
REGULATORY MHLW Calls for Revision of Package Inserts for SGLT-2 Inhibitors

January 13, 2015
ORGANIZATION Price Grouping Rule Triggered “Distortion” in Generic Market: JGA President

January 9, 2015
REGULATORY 30% R&D Tax Deduction Cap Could Be Secured with Open Innovation Tax Break: Economic Affairs Division

January 8, 2015
REGULATORY Public Trust Indispensable for Industry Development: Mr Futagawa of Health Policy Bureau

January 7, 2015
REGULATORY Pharmaceutical and Food Safety Bureau to Promote Prescription-to-OTC Switches Based on Industry Opinions

January 6, 2015
ORGANIZATION FPMAJ Chairman Wishes for Good Environment for Drug Innovation in 2015

January 1, 2015
TRENDS ARBs at a Turning Point: Inroads by Generics to Lead to Gradual Decline in Sales

December 26, 2014
REGULATORY LDP Study Group Shows Sense of Crisis over Reduction of R&D Tax Deduction Cap

December 25, 2014
ORGANIZATION FPMAJ “Hasn’t Given Up” on Maintenance of 30% R&D Tax Deduction Cap: Chairman

December 24, 2014
ORGANIZATION EFPIA Japan Chairman Calls for More Rewards for Innovation

December 22, 2014
BUSINESS Takeda Names Sanofi’s Plump as New R&D Head

December 19, 2014
BUSINESS Daiichi Sankyo Looks to Bring Annual 8-10 Projects into Clinical Phase, Open Innovation Key to Success: R&D Execs

December 18, 2014
BUSINESS CRO Intellim to Collaborate with Indian Firm for CDISC

December 18, 2014
REGULATORY LDP Tax Panel Execs Eye Slight Cut of R&D Tax Deduction Cap

December 17, 2014

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…

COLUMN

More Positions, More Candidates: A Snapshot of Movement in Japan’s Pharma Industry

By Philip Carrigan

Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…